FDA Accepts Supplement for DYNA-HEX 2 by XTTRIUM
The FDA has accepted a supplemental application for DYNA-HEX 2, containing chlorhexidine gluconate.
Published: July 29, 2026
Updated: July 29, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / Antiseptic
Asset: XTTRIUM
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
XTTRIUM
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's acceptance of the supplemental application for DYNA-HEX 2 is a significant regulatory milestone that could strengthen XTTRIUM's competitive position in the antiseptic market. Portfolio teams need to evaluate market dynamics and competitor strategies in response to this development.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further updates on the approval timeline and any competitor responses.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.